 About the EyeGate® II Delivery SystemNON-INVASIVE DRUG DELIVERYEyeGate Pharma’s transscleral iontophoresis delivery platform, the EyeGate® II Delivery System, was originally designed at the Bascom Palmer Eye Institute at the University of Miami and optimized by EyeGate Pharma. EyeGate Pharma’s iontophoresis technology is coulomb-controlled, which means that it regulates each unit of drug delivered for treatment. The EGDS utilizes low voltage electrical current to safely and effectively deliver a wide range of therapeutic types (e.g., low molecular weight compounds, biologics) through its annular ocular applicator. Over 1700 treatments have been performed with the EyeGate® II Delivery System. It is the first ocular iontophoresis system to have completed Phase II studies (Uveitis and Dry Eye) and Phase III studies (Uveitis and Dry Eye). |
|
 |
 |
 |
 |
 |
 |
 |
 |